Astrazeneca knocked by US regulator drug verdict

Julian Harris
Follow Julian
CEO Pascal Soriot boasted of a bright future (Source: Getty Images)
UK pharma giant Astrazeneca was dealt a blow yesterday when US regulators knocked back its bid to gain accelerated approval for a new ovarian cancer drug.

Astrazeneca’s pipeline is under particular scrutiny after chief exec Pascal Soriot boasted of a bright and innovative future while fighting off a £69bn takeover bid from US rival Pfizer last month.

The firm must now submit further clinical data on the new drug.

Related articles